Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone Which Will be Started Randomly at the Ages of 2 to 5, in Children Diagnosed of IUGR

NCT00184691 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00184691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00184691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone Which Will be Started Randomly at the Ages of 2 to 5, in Children Diagnosed of IUGR
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
April 30, 1999
Completion date
June 30, 2005
Enrollment
78 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

foetal growth problem, small for gestational age